Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects

Nutrition and Diabetes - Tập 6 Số 7 - Trang e220-e220
D W L1, Bianca M. Arendt2, Lyn M. Hillyer1, Scott Fung2, Ian D. McGilvray2, Maha Guindi2, Johane P. Allard2
1Department of Human Health and Nutritional Sciences, College of Biological Science, University of Guelph, Guelph, Ontario, Canada
2Toronto General Hospital/University Health Network, Toronto, Ontario, Canada

Tóm tắt

Abstract Background: There is growing evidence that nonalcoholic fatty liver disease (NAFLD) is associated with perturbations in liver lipid metabolism. Liver phospholipid and fatty acid composition have been shown to be altered in NAFLD. However, detailed profiles of circulating lipids in the pathogenesis of NAFLD are lacking. Objective: Therefore, the objective of the present study was to examine circulating lipids and potential mechanisms related to hepatic gene expression between liver biopsy-proven simple steatosis (SS), nonalcoholic steatohepatitis (NASH) and healthy subjects. Subjects: Plasma phospholipid and fatty acid composition were determined in 31 healthy living liver donors as healthy controls (HC), 26 patients with simple hepatic steatosis (SS) and 20 with progressive NASH. Hepatic gene expression was analyzed by Illumina microarray in a subset of 22 HC, 16 SS and 14 NASH. Results: Concentrations of phosphatidylethanolamine (PE) increased relative to disease progression, HC<SS<NASH (170<210<250 μg ml−1), and was significantly different (P<0.05) between HC and NASH. Circulating phosphatidylserine (PS) and phosphatidylinositol were higher in SS and NASH compared with HC (P<0.05), but there was no difference between SS and NASH. Fatty acid composition of phospholipids was also remodeled. In particular, docosahexaenoic and arachidonic acid were higher (P<0.05) in SS and NASH relative to HC in PS. Differentially expressed hepatic genes included ETNK1 and PLSCR1 that are involved in PE synthesis and PS transport, respectively. Conclusions: The present study demonstrates that there is a disruption in phospholipid metabolism that is present in SS, but more pronounced in NASH. Intervention studies targeted at lipid metabolism could benefit SS and NASH.

Từ khóa


Tài liệu tham khảo

Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol 2008; 48: 300–307.

Arendt BM, Mohammed SS, Aghdassi E, Prayitno NR, Ma DW, Nguyen A et al. Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J Nutr 2009; 139: 691–695.

Arendt BM, Mohammed SS, Ma DW, Aghdassi E, Salit IE, Wong DK et al. Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition. Curr HIV Res 2011; 9: 128–135.

Arendt BM, Ma DWL, Simons B, Noureldin S, Therapondos G, Guindi M et al. Non-alcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. Appl Physiol Nutr Metab 2012; 38: 334–340.

Arendt BM, Comelli EM, Ma DW, Lou W, Teterina A, Kim T et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology 2015; 61: 1565–1578.

Nagata S . Apoptosis and autoimmune diseases. Ann N Y Acad Sci 2010; 1209: 10–16.

Nixon GF . Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 2009; 158: 982–993.

Oestvang J, Anthonsen MW, Johansen B . LysoPC and PAF trigger arachidonic acid release by divergent signaling mechanisms in monocytes. J Lipids 2011; 2011: 532145.

Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–2474.

Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.

Folch J, Lees M, Sloane Stanley GH . A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497–509.

Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006; 3: 321–331.

Li Z, Agellon LB, Vance DE . A role for high density lipoproteins in hepatic phosphatidylcholine homeostasis. Biochim Biophys Acta 2007; 1771: 893–900.

Taylor LA, Arends J, Hodina AK, Unger C, Massing U . Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis 2007; 6: 17.

Fuchs B, Schiller J . Lysophospholipids: their generation, physiological role and detection. Are they important disease markers? Mini Rev Med Chem 2009; 9: 368–378.

Hammad SM . Blood sphingolipids in homeostasis and pathobiology. Adv Exp Med Biol 2011; 721: 57–66.

Bikman BT, Summers SA . Sphingolipids and hepatic steatosis. Adv Exp Med Biol 2011; 721: 87–97.

Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res 2011; 52: 509–517.

Cojocaru M, Cojocaru IM, Silosi I . Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases. Maedica (Buchar) 2010; 5: 51–55.

Balla T . Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev 2013; 93: 1019–1137.

Phillips GB, Dodge JT . Composition of phospholipids and of phospholipid fatty acids of human plasma. J Lipid Res 1967; 8: 676–681.

Serna J, Garcia-Seisdedos D, Alcazar A, Lasuncion MA, Busto R, Pastor O . Quantitative lipidomic analysis of plasma and plasma lipoproteins using MALDI-TOF mass spectrometry. Chem Phys Lipids 2015; 189: 7–18.

Camont L, Lhomme M, Rached F, Le GW, Negre-Salvayre A, Salvayre R et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 2013; 33: 2715–2723.

Burgess JW, Neville TA, Rouillard P, Harder Z, Beanlands DS, Sparks DL . Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res 2005; 46: 350–355.

da Costa KA, Sanders LM, Fischer LM, Zeisel SH . Docosahexaenoic acid in plasma phosphatidylcholine may be a potential marker for in vivo phosphatidylethanolamine N-methyltransferase activity in humans. Am J Clin Nutr 2011; 93: 968–974.

Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A et al. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 2004; 110: 1645–1649.

Harris WS, Von Schacky C . The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 2004; 39: 212–220.

Meikle PJ, Barlow CK, Mellett NA, Mundra PA, Bonham MP, Larsen A et al. Postprandial plasma phospholipids in men are influenced by the source of dietary fat. J Nutr 2015; 145: 2012–2018.

Meikle PJ, Mundra PA, Wong G, Rahman K, Huynh K, Barlow CK et al. Circulating lipids are associated with alcoholic liver cirrhosis and represent potential biomarkers for risk assessment. PLoS One 2015; 10: e0130346.

Ratovitski EA . Delta Np63 alpha - responsive microRNA modulate the expression of metabolic enzymes. Curr Pharm Biotechnol 2015; 16: 832–850.

Chang H, Rha SY, Jeung HC, Jung JJ, Kim TS, Kwon HJ et al. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol 2010; 136: 1901–1913.

Dolley G, Lamarche B, Despres JP, Bouchard C, Perusse L, Vohl MC . Phosphoinositide cycle gene polymorphisms affect the plasma lipid profile in the Quebec Family Study. Mol Genet Metab 2009; 97: 149–154.

Rysavy NM, Shimoda LM, Dixon AM, Speck M, Stokes AJ, Turner H et al. Beyond apoptosis: the mechanism and function of phosphatidylserine asymmetry in the membrane of activating mast cells. Bioarchitecture 2014; 4: 127–137.

Vock C, Biedasek K, Boomgaarden I, Heins A, Nitz I, Doring F . ACBP knockdown leads to down-regulation of genes encoding rate-limiting enzymes in cholesterol and fatty acid metabolism. Cell Physiol Biochem 2010; 25: 675–686.

Kondo M, Ishizawa T, Enooku K, Tokuhara Y, Ohkawa R, Uranbileg B et al. Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma. Clin Chim Acta 2014; 433: 128–134.

Thông tin
Thông tin xuất bản

Nutrition and Diabetes

Tập 6 Số 7

e220-e220

Thông tin tác giả